Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy.

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide.
• Current treatments for advanced GC yield limited survival benefits.
• Fibroblast Growth Factor Receptors (FGFRs), particularly FGFR2, are implicated in GC development and progression.

Purpose of the Study:

• To review the biological role of FGFR2 in gastric cancer.
• To summarize FGFR2-targeted agents in clinical trials for GC.
• To discuss challenges in implementing FGFR2-targeted therapies.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of FGFR2 expression and its correlation with GC prognosis.
• Overview of ongoing clinical trials for FGFR2 inhibitors and antibodies in GC.

Main Results:

• FGFR2 is overexpressed in GC, especially diffuse-type, and linked to poor outcomes.
• Multiple small molecule inhibitors and monoclonal antibodies targeting FGFR2 are under investigation.
• These agents are being evaluated as monotherapies and in combination with standard care.

Conclusions:

• FGFR2 represents a significant therapeutic target in gastric cancer.
• Targeted therapies against FGFR2 show promise for improving patient outcomes.
• Overcoming challenges in clinical application is crucial for realizing the full benefit of FGFR2-targeted treatments.